NCT00653419View on ClinicalTrials.gov

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 1998

Primary Completion Date

September 30, 1998

Study Completion Date

September 30, 1998

Conditions
To Determine Bioequivalence Under Fasting Conditions
Interventions
DRUG

buspirone HCl

Tablets, 30 mg, single-dose

DRUG

Buspar

Tablets, 30 mg, single-dose

Trial Locations (1)

H4R 2N6

Phoenix International Life Sciences, Inc., Saint-Laurent

Sponsors
All Listed Sponsors
collaborator

Phoenix International Life Sciences, Inc.

INDUSTRY

lead

Par Pharmaceutical, Inc.

INDUSTRY

NCT00653419 - Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter